CLDX Q3 2021 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$153,000-77.1% YoY

Gross Profit

-$13M-8760.8% margin

Operating Income

-$21M-13610.5% margin

Net Income

-$20M-13367.3% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

-95.6%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$460M

Total Liabilities

$23M

Stockholders' Equity

$437M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$153,000	$668,000	-77.1%
Gross Profit	-$13M	-$10M	-33.5%
Operating Income	-$21M	-$14M	-45.2%
Net Income	-$20M	-$14M	-43.8%

Revenue Segments

Grant

$153,000100%